Myriad caught in Prometheus line of fire; SCOTUS vacates/remands
This article was originally published in Scrip
Executive Summary
The Supreme Court in a 26 March grant-vacate-remand (GVR) order asked the US Court of Appeals for the Federal Circuit to take another look at its July 2011 ruling that Myriad Genetics' composition patent claims covering the BRCA1 and BRCA2 genes are valid and that the isolated DNA molecules do not exist in nature (scripintelligence.com, 1 August 2011, 4 April 2011, 5 April 2011).